These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25120814)

  • 1. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
    Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].
    Zhao J; Zhao J; Zhao X; Chen W; Zhong W; Zhang L; Li L; Wang M
    Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):25-32. PubMed ID: 23327870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
    Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
    Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
    Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
    Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
    Simonetti S; Molina MA; Queralt C; de Aguirre I; Mayo C; Bertran-Alamillo J; Sanchez JJ; Gonzalez-Larriba JL; Jimenez U; Isla D; Moran T; Viteri S; Camps C; Garcia-Campelo R; Massuti B; Benlloch S; Ramon y Cajal S; Taron M; Rosell R
    J Transl Med; 2010 Dec; 8():135. PubMed ID: 21167064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
    Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
    Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
    Jiang G; Fan C; Zhang X; Dong Q; Wang L; Liu Y; Dai S; Yang L; Zhang Y; Yu J; Wang E
    PLoS One; 2013; 8(3):e59183. PubMed ID: 23536868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.